FDA okays start of BrainStorm stem cell trial in ALS patients – WTAQ
|
FDA okays start of BrainStorm stem cell trial in ALS patients
WTAQ TEL AVIV (Reuters) – BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS). The Phase II trial … |
